

[Mercaptopurine](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01BB02](#)

EMLc

Indication

Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: [2A60.0](#)

INN

Mercaptopurine

Medicine type

Chemical agent

List type

Complementary

Formulations

Oral > Liquid: 20 mg per mL (EMLc)

Oral > Solid: 50 mg tablet

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Mercaptopurine](#)

DrugBank

[Mercaptopurine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of mercaptopurine (oral liquid 20 mg/mL) to the EMLc.